An Oxymetazoline-Based Hemostatic Solution Used with MTA for Pulpal Therapy: A Retrospective Study

<b>Background/Objectives:</b> The purpose of this study is to assess whether the addition of an oxymetazoline (OXY) hemostatic solution, which can be used to manage pulpal bleeding, maintains higher MTA survivability than pulpotomies treated with FS. <b>Methods</b>: In this retrospective cross-sectional study, patient data (<i>n</i> = 75) were used to assess radiographic and clinical signs and symptoms of pathosis in primary molars treated with a pulpotomy and a stainless-steel crown. Pulpotomies treated with FS (Group 1) were compared to those treated with MTA with OXY-induced hemostasis (Group 2). Restricted mean survival times (RMSTs) were calculated for the two groups, and Cox proportional hazards regression was used to analyze the effects of patient and practice level covariates on radiographic and clinical pathosis. <b>Results</b>: Cox proportional-hazard regression identified three potential covariates (age, pulpotomy groups, and procedure location) that predicted radiographic pathosis. The adjusted hazard ratio for Group 2 was 0.30 (95% CI: 0.11-0.82), indicating improved radiographic outcomes compared with Group 1 (<i>p</i> = 0.02). The 36-month RMST for Group 2 was 30.1 months (95% CI: 26.5-33.7) compared to 24.7 months (21.6-27.8) for Group 1 (<i>p</i> = 0.025). <b>Conclusions</b>: A pulpotomy utilizing OXY hemostasis prior to MTA placement led to a higher chance of pulpotomy survival than FS.